HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.4%

Neg 0% Neu 89.4% Pos 0%

HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $30 price target.